Ignite Creation Date:
2024-05-05 @ 5:34 PM
Last Modification Date:
2024-10-26 @ 9:33 AM
Study NCT ID:
NCT00483132
Status:
COMPLETED
Last Update Posted:
2007-06-06
First Post:
2007-06-05
Brief Title:
Study of Treatment High Risk andor Low Risk Acute Lymphoblastic leukémiaALL Adults Stage III
Sponsor:
French Innovative Leukemia Organisation
Organization:
French Innovative Leukemia Organisation
Study Overview
Official Title:
Study of Treatment High Risk andor Low Risk Acute Lymphoblastic leukémiaALL Adults Stage III
Status:
COMPLETED
Status Verified Date:
2007-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Improved outcome of high risk lymphoblastic leukemia ALL with laite high dose therapy
High dose versus conventional therapy for adult low risk T-ALL and Lymphoblastic lymphoma LBL
High dose versus conventional therapy for adult low risk T-ALL and Lymphoblastic lymphoma LBL
Detailed Description:
Comparison between two autograf therapeutic strategies in high risk patients Ramdomised comparison between maintenance treatment with or not interferon alpha 2 a
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None